The latest biotech news

News and Trends 2 Aug 2022

Success across the board for C4X Discovery Holdings plc and its partnerships

Drug discovery company C4X Discovery Holdings plc released a report today (August 2) detailing the continued success of its relationship with partners across its portfolio. The company says it is happy to report it received its first milestone payment last month of €3 million ($3.1 million) from Sanofi under the out-licensing agreement for its IL-17A […]

August 2, 2022 - 3 minutesmins - By Liza Laws

News and Trends 2 Aug 2022

MAIA Biotechnology raises $10M from public offering

U.S. clinical stage company MAIA Biotechnology, Inc. has closed its initial public offering of 2,000,000 shares of the company’s common stock at a public offering price of $5.00 per share. The gross proceeds from the initial public offering were $10 million, prior to deducting underwriting discounts, commissions, and other offering expenses. The company has granted […]

August 2, 2022 - 2 minutesmins - By Jim Cornall

cancer shutterstock immunotherapy deep science ventures

News and Trends 2 Aug 2022

IDRx launches with $122M to treat cancer with precision combination therapies

DRx, Inc., a clinical-stage biopharmaceutical company, launched today with a $122 million oversubscribed series A financing. The financing was led by Andreessen Horowitz (a16z) and Casdin Capital, with participation from Nextech Invest, Forge Life Science Partners and other undisclosed investors. Inspired by a few curative combination regimens in cancer and the successful drug cocktails engineered […]

August 2, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 2 Aug 2022

FDA gives ok to Krystal Biotech cystic fibrosis clinical trial

U.S. company Krystal Biotech is set to start a clinical trial for cystic fibrosis after the United States Food and Drug Administration (FDA) accepted its investigational new drug (IND) application. The gene therapy company will be evaluating KB407, a modified HSV-1 vector carrying two copies of the cystic fibrosis transmembrane conductance regulator (CFTR) gene to […]

August 2, 2022 - 3 minutesmins - By Jim Cornall

Sanofi drops amcenestrant clinical development program

News and Trends 2 Aug 2022

Defence Therapeutics says AccuTOX kills cancer cells

Defence Therapeutics Inc., a Canadian biopharma company specializing in immune-oncology vaccines and drug delivery technologies, says it has discovered a novel DNA damaging function triggered by one of its lead compounds AccuTOX, which effectively elicits cell death in cancer cells. Cancer can be generally described as a state of uncontrolled cell proliferation. This is mainly […]

August 2, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 2 Aug 2022

Glycostem and medac sign deal on AML and MM product

Glycostem Therapeutics B.V. and medac GmbH are to partner to commercialize Glycostem’s lead product, oNKord. oNKord is currently in a phase 1/2 clinical trial across 10 hospitals in five European countries. Glycostem is a Dutch clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf natural killer (NK) cells, and medac is an international pharmaceutical […]

August 2, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 2 Aug 2022

Cellectis gets green light for non-Hodgkin lymphoma trial

French-headquartered gene-editing biotech company Cellectis says the U.S. Food and Drug Administration (FDA) has cleared Cellectis’ Investigational New Drug (IND) application to initiate a phase 1/2a clinical trial of UCART20x22 for patients with relapsed or refractory non-Hodgkin lymphoma (r/r NHL). The company plans to begin enrolling patients in the NatHaLi-01 study in the second half […]

August 2, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 2 Aug 2022

COUR NanoParticle technology halts Type 1 diabetes progression

COUR Pharmaceuticals has published details of a study with the Miller Lab at Northwestern University, looking at type 1 diabetes. COUR develops novel immune-modifying nanoparticles (COUR NanoParticles or CNPs) designed to reprogram the immune system in treating autoimmune disorders. The data demonstrated durable tolerance using its novel platform technology in the non-obese diabetic (NOD) model […]

August 2, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 2 Aug 2022

SNIPR Biome announces new patent granted for applications targeting E. coli infections

SNIPR Biome has today (August 2) announced that it has been granted a patent for medical applications supporting the company’s lead program – a bacteriophage cocktail targeting E.coli infections. Granted by the US Patent and Trademark Office (USPTO), the patent adds to its intellectual property portfolio that contains more than 20 granted patents in the […]

August 2, 2022 - 2 minutesmins - By Liza Laws

News and Trends 2 Aug 2022

Sosei Heptares and AbbVie enter second collaboration targeting neurological diseases

A new drug discovery collaboration has taken place between Japanese Sosei Group Corporation and UK-based Abbvie with the hope of targeting neurological disease. This is the second partnership between the companies and offers the option to license agreement which is aimed at discovering, developing and commercializing small molecules that modulate novel G protein-coupled receptor (GPCR) […]

August 2, 2022 - 2 minutesmins - By Liza Laws

News and Trends 1 Aug 2022

Arecor Therapeutics adds diabetes product to portfolio after significant acquisition

Arecor Therapeutics plc has bought all of Tetris Pharma Ltd shares adding a key commercial diabetes product to its portfolio. The company says as well as expanding its portfolio, the acquisition of the entire issued share capital complements its existing hospital products franchise and will speed up its revenue growth. Injectable products Tetris Pharma has […]

August 1, 2022 - 3 minutesmins - By Liza Laws

News and Trends 1 Aug 2022

FDA puts clinical hold on Beam Theraputics’ cancer therapy

Beam Therapeutics Inc., a U.S. biotech company developing precision genetic medicines through base editing, says the company was informed via email last week that the U.S. Food and Drug Administration (FDA) has placed a hold on the BEAM-201 Investigational New Drug (IND) application for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL)/T cell lymphoblastic […]

August 1, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Success across the board for C4X Discovery Holdings plc and its partnerships

MAIA Biotechnology raises $10M from public offering

IDRx launches with $122M to treat cancer with precision combination therapies

FDA gives ok to Krystal Biotech cystic fibrosis clinical trial

Defence Therapeutics says AccuTOX kills cancer cells

Glycostem and medac sign deal on AML and MM product

Cellectis gets green light for non-Hodgkin lymphoma trial

COUR NanoParticle technology halts Type 1 diabetes progression

SNIPR Biome announces new patent granted for applications targeting E. coli infections

Sosei Heptares and AbbVie enter second collaboration targeting neurological diseases

Arecor Therapeutics adds diabetes product to portfolio after significant acquisition

FDA puts clinical hold on Beam Theraputics’ cancer therapy

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!